You are here: Industry Insights > Bristol-Myers

News List

Bluebird bio, Bristol-Myers’ multiple myeloma therapy shows promise in early study expresspharma
December 12, 2019
Bluebird bio Inc and Bristol-Myers Squibb Co recently reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.
Bristol-Myers Squibb Announces Opdivo Glioblastoma Study Does Not Meet PFS Primary Endpoint americanpharmaceuticalreview
September 06, 2019
Bristol-Myers Squibb announced that the Phase 3 CheckMate -548 trial evaluating the addition of Opdivo (nivolumab) to the current standard of care (temozolomide and radiation therapy) versus the standard ...
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement worldpharmanews
July 19, 2019
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement.
Bristol-Myers' Opdivo fails brain tumor test again, this time in new patients fiercepharma
May 12, 2019
Cancer immunotherapies can effectively tackle many tumor types. But for notoriously hard-to-treat brain cancer—and after a couple of failed trials—hope seems less realistic, at least for Bristol-Myers Squibb’s Opdivo.
Bristol-Myers Squibb and Infinity to collaborate on Opdivo (nivolumab) plus IPI-549 solid tumours study europeanpharmaceuticalreview
May 08, 2019
Bristol-Myers Squibb and Infinity will collaborate on a solid tumours trial to evaluate Bristol-Myers Squibb’s Opdivo in combination with Infinity’s…
Novartis & Bristol-Myers Squibb to collaborate on cancer treatments europeanpharmaceuticalreview
May 07, 2019
Novartis has entered into a research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist…
BioGeneration Ventures Fund III Reaches EUR 82 Million in Final Close .b3cnewswire
April 23, 2019
Investments from Bristol-Myers Squibb and Johnson & Johnson Innovation - JJDC.
Bristol-Myers $74bn Celgene takeover gets shareholders approvals pharmaceutical-technology
April 23, 2019
Bristol-Myers $74bn Celgene takeover gets shareholders approvals...
Bristol-Myers Squibb shareholders approve Celgene acquisition worldpharmanews
April 16, 2019
Bristol-Myers Squibb shareholders approve Celgene acquisition.
Nobel laureate behind Bristol-Myers' I-O superstar Opdivo demands a bigger cut fiercepharma
April 12, 2019
Opdivo, the blockbuster cancer drug Bristol-Myers Squibb co-developed with Japan’s Ono Pharmaceutical, is a cash cow in the global market. But a Nobel laureate who helped create the drug isn’t happy with his cut.

Previous page 1 2 3 4 5 Next page